Lv6
2530 积分 2022-06-14 加入
Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: the phase I/II randomized NAPAN trial
1个月前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
2个月前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
2个月前
已完结
An overview of KRAS G12D inhibitors: Expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities
2个月前
已完结
The role of alternative splicing in cancer drug resistance
2个月前
已完结
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
2个月前
已完结
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
3个月前
已完结
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
3个月前
已完结
Autoimmune diseases: targets, biology, and drug discovery
3个月前
已完结
Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management
4个月前
已完结
皖公网安备34019202002308
